{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T17:56:36Z","timestamp":1785606996476,"version":"3.56.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"DOI":"10.1007\/s10689-026-00595-8","type":"journal-article","created":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:33:50Z","timestamp":1785558830000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mainstream and fast-track genetic testing in pancreatic cancer patients and its impact on treatment: our experience in a tertiary hospital in Spain"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8266-705X","authenticated-orcid":false,"given":"M.","family":"Bringas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Echavarr\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Polo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Jim\u00e9nez-Aldu\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Soto-Alsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Garc\u00eda","family":"Alfonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Pajares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Su\u00e1rez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"del Monte-Mill\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Massarrah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Ayala","family":"de la Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"M\u00e1rquez-Rodas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,1]]},"reference":[{"key":"595_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.3829","author":"T Conroy","year":"2022","unstructured":"Conroy T, Castan F, Lopez A, Turpin A, Ben Abdelghani M, Wei AC et al (2022) Five-year outcomes of FOLFIRINOX vs Gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2022.3829","journal-title":"JAMA Oncol"},{"key":"595_CR2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00298","author":"M Dbouk","year":"2022","unstructured":"Dbouk M, Katona BW, Brand RE, Chak A, Syngal S, Farrell JJ et al (2022) The multicenter cancer of pancreas screening study: impact on stage and survival. J Clin Oncol Off J Am Soc Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.22.00298","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"595_CR3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s12094-019-02262-0","volume":"22","author":"SE Gonz\u00e1lez-Santiago","year":"2020","unstructured":"Gonz\u00e1lez-Santiago SE, Ram\u00f3n y CajalAguirreAl\u00e9s-Mart\u00ednezAndr\u00e9sBalma\u00f1a TEJERJ et al (2020) SEOM clinical guidelines in hereditary breast and ovarian cancer (2019). Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex. 22(2):193\u2013200. https:\/\/doi.org\/10.1007\/s12094-019-02262-0","journal-title":"Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex."},{"issue":"2","key":"595_CR4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s12094-019-02272-y","volume":"22","author":"C Guill\u00e9n-Ponce","year":"2020","unstructured":"Guill\u00e9n-Ponce C, Lastra E, Lorenzo-Lorenzo I, Mart\u00edn G\u00f3mez T, Morales Chamorro R, S\u00e1nchez-Heras AB et al (2020) SEOM clinical guideline on hereditary colorectal cancer (2019). Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex 22(2):201\u2013212. https:\/\/doi.org\/10.1007\/s12094-019-02272-y","journal-title":"Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex"},{"issue":"9","key":"595_CR5","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1007\/s12094-023-03202-9","volume":"25","author":"AB S\u00e1nchez-Heras","year":"2023","unstructured":"S\u00e1nchez-Heras AB, Ramon y CajalPinedaAguirreGra\u00f1aChirivella TMEBI et al (2023) SEOM clinical guideline on heritable TP53-related cancer syndrome (2022). Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex 25(9):2627\u20132633. https:\/\/doi.org\/10.1007\/s12094-023-03202-9","journal-title":"Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex"},{"key":"595_CR6","unstructured":"C\u00e1ncer hereditario (2019) Madrid: Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica."},{"key":"595_CR7","unstructured":"FlippingBook (2024) [Internet]. [citado 9 de julio de 2026]. Manual de Prevencion 2024. Disponible en: https:\/\/seom.org\/manual-prevencion-2\/"},{"issue":"11","key":"595_CR8","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","volume":"34","author":"T Conroy","year":"2023","unstructured":"Conroy T, Pfeiffer P, Vilgrain V, Lamarca A, Seufferlein T, O\u2019Reilly EM et al (2023) Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol 34(11):987\u20131002. https:\/\/doi.org\/10.1016\/j.annonc.2023.08.009","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"5","key":"595_CR9","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1007\/s12094-021-02573-1","volume":"23","author":"MA G\u00f3mez-Espa\u00f1a","year":"2021","unstructured":"G\u00f3mez-Espa\u00f1a MA, Montes AF, Garcia-Carbonero R, Mercad\u00e9 TM, Maurel J, Mart\u00edn AM et al (2021) SEOM clinical guidelines for pancreatic and biliary tract cancer (2020). Clin Transl Oncol mayo de 23(5):988\u20131000. https:\/\/doi.org\/10.1007\/s12094-021-02573-1","journal-title":"Clin Transl Oncol mayo de"},{"issue":"18","key":"595_CR10","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691\u20131703. https:\/\/doi.org\/10.1056\/NEJMoa1304369","journal-title":"N Engl J Med"},{"issue":"4","key":"595_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ et al (2019) Maintenance Olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 381(4):317\u2013327. https:\/\/doi.org\/10.1056\/NEJMoa1903387","journal-title":"N Engl J Med"},{"issue":"1","key":"595_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP et al (2020) Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol Off J Am Soc Clin Oncol. 38(1):1\u201310. https:\/\/doi.org\/10.1200\/JCO.19","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"1","key":"595_CR13","doi-asserted-by":"publisher","first-page":"e000578","DOI":"10.1136\/esmoopen-2019-000578","volume":"5","author":"I Pokataev","year":"2020","unstructured":"Pokataev I, Fedyanin M, Polyanskaya E, Popova A, Agafonova J, Menshikova S et al (2020) Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies. ESMO Open 5(1):e000578. https:\/\/doi.org\/10.1136\/esmoopen-2019-000578","journal-title":"ESMO Open"},{"issue":"34","key":"595_CR14","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1200\/JCO.21.01604","volume":"40","author":"HL Kindler","year":"2022","unstructured":"Kindler HL, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ et al (2022) Overall survival results from the POLO trial: a phase III study of active maintenance Olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol Off J Am Soc Clin Oncol 40(34):3929\u20133939. https:\/\/doi.org\/10.1200\/JCO.21.01604","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"595_CR15","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_321255","author":"MS Lee","year":"2021","unstructured":"Lee MS, Pant S (2021) Personalizing medicine with germline and somatic sequencing in advanced pancreatic cancer: current treatments and novel opportunities. Am Soc Clin Oncol Educ Book. https:\/\/doi.org\/10.1200\/EDBK_321255","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"595_CR16","doi-asserted-by":"publisher","first-page":"e236","DOI":"10.1200\/OP.20.00678","volume":"17","author":"A Chittenden","year":"2021","unstructured":"Chittenden A, Haraldsdottir S, Ukaegbu C, Underhill-Blazey M, Gaonkar S, Uno H et al (2021) Implementing systematic genetic counseling and multigene germline testing for individuals with pancreatic cancer. JCO Oncol Pract febrero de 17(2):e236\u2013e247. https:\/\/doi.org\/10.1200\/OP.20.00678","journal-title":"JCO Oncol Pract febrero de"},{"issue":"3","key":"595_CR17","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1245\/s10434-022-12755-y","volume":"30","author":"NM Clark","year":"2023","unstructured":"Clark NM, Roberts EA, Fedorenko C, Sun Q, Dubard-Gault M, Handford C et al (2023) Genetic testing among patients with high-risk breast, ovarian, pancreatic, and prostate cancers. Ann Surg Oncol marzo de 30(3):1312\u20131326. https:\/\/doi.org\/10.1245\/s10434-022-12755-y","journal-title":"Ann Surg Oncol marzo de"},{"issue":"2","key":"595_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s10689-018-0106-2","volume":"18","author":"EJ Walker","year":"2019","unstructured":"Walker EJ, Carnevale J, Pedley C, Blanco A, Chan S, Collisson EA et al (2019) Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma. Fam Cancer 18(2):241\u2013251. https:\/\/doi.org\/10.1007\/s10689-018-0106-2","journal-title":"Fam Cancer"},{"issue":"1","key":"595_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s10689-022-00300-5","volume":"22","author":"ML Ramsey","year":"2023","unstructured":"Ramsey ML, Tomlinson J, Pearlman R, Abushahin L, Aeilts A, Chen HZ et al (2023) Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake. Fam Cancer enero de 22(1):91\u201397. https:\/\/doi.org\/10.1007\/s10689-022-00300-5","journal-title":"Fam Cancer enero de"},{"issue":"9","key":"595_CR20","doi-asserted-by":"publisher","first-page":"e2431427","DOI":"10.1001\/jamanetworkopen.2024.31427","volume":"7","author":"Z Rezoug","year":"2024","unstructured":"Rezoug Z, Totten SP, Szlachtycz D, Atayan A, Mohler K, Albert S et al (2024) Universal genetic testing for newly diagnosed invasive breast cancer. JAMA Netw Open 7(9):e2431427. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.31427","journal-title":"JAMA Netw Open"},{"issue":"1","key":"595_CR21","doi-asserted-by":"publisher","first-page":"29506","DOI":"10.1038\/srep29506","volume":"6","author":"A George","year":"2016","unstructured":"George A, Riddell D, Seal S, Talukdar S, Mahamdallie S, Ruark E et al (2016) Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients. Sci Rep 6(1):29506. https:\/\/doi.org\/10.1038\/srep29506","journal-title":"Sci Rep"},{"issue":"5","key":"595_CR22","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1097\/JU.0000000000003186","volume":"209","author":"KE Breen","year":"2023","unstructured":"Breen KE, Symecko H, Spielman K, Gebert R, Shah IH, Pundock S et al (2023) Clinical impact of a rapid genetic testing model for advanced prostate cancer patients. J Urol mayo de 209(5):918\u2013927. https:\/\/doi.org\/10.1097\/JU.0000000000003186","journal-title":"J Urol mayo de"},{"key":"595_CR23","unstructured":"Ministerio de Sanidad - Profesionales de la Salud - Buscador situaci\u00f3n financiaci\u00f3n medicamentos [Internet]. [citado 12 de febrero de 2026]. Disponible en: https:\/\/www.sanidad.gob.es\/va\/profesionales\/medicamentos.do?metodo=verDetalle&cn=721826"},{"key":"595_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/srep29506","author":"A George","year":"2016","unstructured":"George A, Riddell D, Seal S, Talukdar S, Mahamdallie S, Ruark E et al (2016) Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients. Sci Rep. https:\/\/doi.org\/10.1038\/srep29506","journal-title":"Sci Rep"},{"issue":"1","key":"595_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1245\/s10434-024-16223-7","volume":"32","author":"V Shim","year":"2024","unstructured":"Shim V, Karlea A, Brenman LM, Gul J, Hoodfar E, Chan TD et al (2024) Mainstream germline genetic testing with expanded eligibility for early breast cancer patients in a large integrated health system. Ann Surg Oncol 32(1):75. https:\/\/doi.org\/10.1245\/s10434-024-16223-7","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"595_CR26","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.1200\/OP.20.00399","volume":"17","author":"T Scheinberg","year":"2021","unstructured":"Scheinberg T, Goodwin A, Ip E, Linton A, Mak B, Smith DP et al (2021) Evaluation of a mainstream model of genetic testing for men with prostate cancer. JCO Oncol Pract febrero de 17(2):e204\u2013e216. https:\/\/doi.org\/10.1200\/OP.20.00399","journal-title":"JCO Oncol Pract febrero de"},{"issue":"3","key":"595_CR27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/ajco.13334","volume":"17","author":"T Scheinberg","year":"2021","unstructured":"Scheinberg T, Young A, Woo H, Goodwin A, Mahon KL, Horvath LG (2021) Mainstream consent programs for genetic counseling in cancer patients: a systematic review. Asia Pac J Clin Oncol 17(3):163\u2013177. https:\/\/doi.org\/10.1111\/ajco.13334","journal-title":"Asia Pac J Clin Oncol"},{"issue":"13","key":"595_CR28","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1200\/JCO.2017.76.2781","volume":"36","author":"N Colombo","year":"2018","unstructured":"Colombo N, Huang G, Scambia G, Chalas E, Pignata S, Fiorica J et al (2018) Evaluation of a streamlined oncologist-led BRCA mutation testing and counseling model for patients with ovarian cancer. J Clin Oncol 36(13):1300\u20131307. https:\/\/doi.org\/10.1200\/JCO.2017.76.2781","journal-title":"J Clin Oncol"},{"key":"595_CR29","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.breast.2023.03.017","volume":"69","author":"K Bokkers","year":"2023","unstructured":"Bokkers K, Bleiker EMA, Velthuizen ME, Koelemij R, Burgmans JPJ, Klinkenbijl JH et al (2023) Patients\u2019 experiences with pre-test genetic counseling provided by breast cancer healthcare professionals: results from a large prospective multicenter study. Breast 69:349\u2013357. https:\/\/doi.org\/10.1016\/j.breast.2023.03.017","journal-title":"Breast"},{"issue":"5","key":"595_CR30","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1097\/JU.0000000000002865","volume":"208","author":"SM Abusamra","year":"2022","unstructured":"Abusamra SM, Solorzano MA, Luke M, Quarles J, Jacobs MF, Kaffenberger S et al (2022) Satisfaction with clinician-led germline genetic counseling in men with prostate cancer. J Urol 208(5):1007\u20131017. https:\/\/doi.org\/10.1097\/JU.0000000000002865","journal-title":"J Urol"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-026-00595-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10689-026-00595-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-026-00595-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T17:02:29Z","timestamp":1785603749000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10689-026-00595-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["595"],"URL":"https:\/\/doi.org\/10.1007\/s10689-026-00595-8","relation":{},"ISSN":["1573-7292"],"issn-type":[{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]},"assertion":[{"value":"7 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Marianela Bringas declares: Honoraria: AstraZeneca, MSD, Almirall, Novartis, Regeneron; Travel accommodation and congress: MSD, Lilly, Pierre-Fabre, Novartis. Iv\u00e1n M\u00e1rquez-Rodas declares Advisory role: Amgen, Astra Zeneca, BiolineRx, BMS, Celegene, GSK, Highlight Therapeutics, Immunocore, Merck Serono, MSD, Novartis, Pierre Fabre, Regeneron, Roche, Sanofi, Sun Pharma; Travel accommodation and congress: Amgen, BMS, GSK, Highlight Therapeutics, MSD, Novartis, Pierre Fabre, Roche, Sun Pharma; Clinical trial participation as PI: Ab Science, Aduro, Agenus, Alkermes, Amgen, Astra Zeneca, Biontech, BMS, Celltrion, Erasca, Genentech, GSK, Highlight Therapeutics, Idera, Immunocore, Incyte, Iovance, Kartos, Merck Serono, MSD, Novartis, Pfizer, Regeneron, Roche, Sairopa. The rest of the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human participants (UCHF 2010-RETRO) was reviewed and approved by the Ethics Committee of Hospital General Universitario Gregorio Mara\u00f1\u00f3n. Informed consent has been obtained for all involving patients.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"80"}}